Morgan Stanley’s Impax Laboratories, Inc. IPXL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q2 | – | Sell |
-873,816
| Closed | -$17M | – | 6910 |
|
|
2018
Q1 | $17M | Buy |
873,816
+561,455
| +180% | +$11M | ﹤0.01% | 1816 |
|
|
2017
Q4 | $5.2M | Buy |
312,361
+205,654
| +193% | +$3.77M | ﹤0.01% | 3077 |
|
|
2017
Q3 | $2.17M | Sell |
106,707
-83,727
| -44% | -$1.6M | ﹤0.01% | 3809 |
|
|
2017
Q2 | $3.07M | Buy |
190,434
+85,955
| +82% | +$1.27M | ﹤0.01% | 3372 |
|
|
2017
Q1 | $1.32M | Sell |
104,479
-193,479
| -65% | -$2.34M | ﹤0.01% | 4170 |
|
|
2016
Q4 | $3.95M | Buy |
297,958
+164,413
| +123% | +$2.81M | ﹤0.01% | 3243 |
|
|
2016
Q3 | $3.17M | Buy |
133,545
+127,105
| +1,974% | +$3.42M | ﹤0.01% | 3118 |
|
|
2016
Q2 | $185K | Sell |
6,440
-8,894
| -58% | -$290K | ﹤0.01% | 4980 |
|
|
2016
Q1 | $491K | Sell |
15,334
-800,945
| -98% | -$28.2M | ﹤0.01% | 4456 |
|
|
2015
Q4 | $34.9M | Buy |
816,279
+256,788
| +46% | +$10.3M | 0.01% | 1017 |
|
|
2015
Q3 | $19.7M | Sell |
559,491
-208,779
| -27% | -$9.41M | 0.01% | 1393 |
|
|
2015
Q2 | $35.3M | Sell |
768,270
-101,042
| -12% | -$4.8M | 0.01% | 1074 |
|
|
2015
Q1 | $40.7M | Buy |
869,312
+19,606
| +2% | +$780K | 0.02% | 968 |
|
|
2014
Q4 | $26.9M | Buy |
849,706
+837,655
| +6,951% | +$24.5M | 0.01% | 1236 |
|
|
2014
Q3 | $286K | Sell |
12,051
-21,816
| -64% | -$559K | ﹤0.01% | 4937 |
|
|
2014
Q2 | $1.01M | Sell |
33,867
-69,487
| -67% | -$1.87M | ﹤0.01% | 4042 |
|
|
2014
Q1 | $2.73M | Buy |
103,354
+41,418
| +67% | +$1.04M | ﹤0.01% | 3156 |
|
|
2013
Q4 | $1.56M | Sell |
61,936
-38,395
| -38% | -$856K | ﹤0.01% | 3576 |
|
|
2013
Q3 | $2.05M | Buy |
100,331
+70,601
| +237% | +$1.46M | ﹤0.01% | 3192 |
|
|
2013
Q2 | $593K | Buy |
+29,730
| New | +$528K | ﹤0.01% | 4142 |
|
Morgan Stanley's IPXL Position: Q2 2018 in Review
Morgan Stanley sold out of Impax Laboratories, Inc. (IPXL) in Q2 2018, closing a stake of 873,816 shares — an estimated $17M sold.
Morgan Stanley first reported a position in IPXL in Q2 2013 and held it in 20 quarters. The position peaked at $40.7M in Q1 2015. 1 fund tracked by Wall St. Rank holds IPXL as of Q2 2018.
- Morgan Stanley reported no remaining Impax Laboratories, Inc. position as of Q2 2018 after selling out during the quarter.
- Morgan Stanley sold 873,816 Impax Laboratories, Inc. shares in Q2 2018, an estimated $17M.
- Morgan Stanley first reported a position in Impax Laboratories, Inc. in Q2 2013 and held it in 20 quarters.
- Morgan Stanley's Impax Laboratories, Inc. position peaked at $40.7M in Q1 2015.
- 1 fund tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q2 2018.
Based on Morgan Stanley's 13F filing for Q2 2018, filed 14 Aug 2018.